Why the study?
Does early management with antivirals, immunomodulators, ascorbic acid, melatonin, and immunoglobulins improve clinical condition and LVEF in a patient with COVID-19-related fulminant myocarditis?
Does early management with antivirals, immunomodulators, ascorbic acid, melatonin, and immunoglobulins improve clinical condition and LVEF in a patient with COVID-19-related fulminant myocarditis?
Early management with immunomodulatory and supportive therapies may improve cardiac function in elderly patients with COVID-19-related fulminant myocarditis.
Answers are grounded in this paper and cite their sources.
May support multimodal therapy in COVID-19 myocarditis; hypothesis-generating and requires prospective validation.
A 78-year-old man with COVID-19 infection was admitted. Initial echocardiography indicated left ventricular ejection fraction (LVEF) of 15%, high pulmonary arterial pressure, severe left ventricular dysfunction, mild diastolic dysfunction, mild regurgitation mitral valve, and normal septal thickness. Considering the probable diagnosis of COVID-19-related myocarditis, the patient was early managed with the antivirals, immunomodulatory agents, a high dose of ascorbic acid, melatonin, and immunoglobulin therapy. His clinical condition was improved and his last echocardiography revealed LVEF of 40% and improvement in systolic and diastolic dysfunction. The clinicians should be aware of the potentially lethal cardiac complication of COVID-19, especially in geriatrics.
No takes yet. Share an insight, caveat, or question.
Shahrami et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: